for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Myokardia Inc

MYOK.OQ

現在値

222.40USD

変化

0.00(0.00%)

出来高

162,118

本日のレンジ

222.40

 - 

222.76

52週レンジ

42.75

 - 

223.96

∙ 約20分前の相場を表示しています。

適時開示

Bristol To Pay $13.1 Billion For Heart-Drug Maker Myokardia - WSJ

Oct 5 (Reuters) - :BRISTOL TO PAY $13.1 BILLION FOR HEART-DRUG MAKER MYOKARDIA - WSJ.BRISTOL TO PAY $225 A SHARE FOR MYOKARDIA- WSJ.

Bristol Myers Squibb To Acquire Myokardia For $13.1 Bln In Cash

Oct 5 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::BRISTOL MYERS SQUIBB TO ACQUIRE MYOKARDIA FOR $13.1 BILLION IN CASH.BRISTOL MYERS SQUIBB TO ACQUIRE MYOKARDIA FOR $13.1 BILLION IN CASH.BRISTOL-MYERS SQUIBB CO - DEAL EXPECTED TO BE ACCRETIVE TO NON-GAAP EARNINGS STARTING IN 2023.BRISTOL-MYERS SQUIBB CO - BRISTOL MYERS SQUIBB WILL ACQUIRE MYOKARDIA FOR $13.1 BILLION, OR $225.00 PER SHARE IN CASH.BRISTOL-MYERS SQUIBB CO - EXPECTED TO BE ACCRETIVE TO NON-GAAP EARNINGS STARTING IN 2023.BRISTOL-MYERS SQUIBB CO - TRANSACTION WAS UNANIMOUSLY APPROVED BY BOTH BRISTOL MYERS SQUIBB AND MYOKARDIA BOARDS.BRISTOL-MYERS SQUIBB CO - REAFFIRMS ITS EXISTING 2021 NON-GAAP EPS GUIDANCE RANGE.BRISTOL-MYERS - DEAL EXPECTED TO BE MINIMALLY DILUTIVE TO BRISTOL'S NON-GAAP EPS IN 2021 AND 2022 AND ACCRETIVE BEGINNING IN 2023.BRISTOL-MYERS SQUIBB CO - EXPECTS TO FINANCE ACQUISITION WITH A COMBINATION OF CASH AND DEBT.BRISTOL-MYERS SQUIB - EXPECTS TO EXPLORE FULL POTENTIAL OF MAVACAMTEN IN ADDITIONAL INDICATIONS, INCLUDING NON-OBSTRUCTIVE HCM.

MyoKardia and LianBio Partner to Develop Mavacamten in Greater China

Aug 11 (Reuters) - MyoKardia Inc <MYOK.O>::MYOKARDIA AND LIANBIO FORM STRATEGIC PARTNERSHIP TO DEVELOP AND COMMERCIALIZE MAVACAMTEN TOGETHER IN GREATER CHINA.MYOKARDIA INC - MYOKARDIA WILL A RECEIVE A PAYMENT OF $40 MILLION AT CLOSING.MYOKARDIA INC - MYOKARDIA MAY BE ELIGIBLE TO RECEIVE REGULATORY AND SALES MILESTONE PAYMENTS OF UP TO $147.5 MILLION.MYOKARDIA INC - LIANBIO WILL FUND ALL DEVELOPMENT AND COMMERCIAL EXPENSES IN COLLABORATION TERRITORY.MYOKARDIA - MYOKARDIA RECEIVES EQUITY POSITION IN LIAN CARDIOVASCULAR AND TASSOS GIANAKAKOS, MYOKARDIA'S CEO, TO JOIN LIANBIO BOARD.

Myokardia Reports Second Quarter 2020 Financial Results

Aug 4 (Reuters) - MyoKardia Inc <MYOK.O>::MYOKARDIA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.27.Q2 EARNINGS PER SHARE ESTIMATE $-1.46 -- REFINITIV IBES DATA.

Myokardia And Fulcrum Therapeutics Announce Multi-Target Collaboration To Discover Novel Targeted Therapies For Genetic Cardiomyopathies

July 21 (Reuters) - Fulcrum Therapeutics Inc <FULC.O>::MYOKARDIA AND FULCRUM THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO DISCOVER NOVEL TARGETED THERAPIES FOR GENETIC CARDIOMYOPATHIES.FULCRUM THERAPEUTICS INC - FULCRUM WILL RECEIVE A PAYMENT OF $12.5 MILLION AT CLOSE.FULCRUM THERAPEUTICS - FULCRUM MAY BE ELIGIBLE TO RECEIVE MILESTONE PAYMENTS AND ADDITIONAL RESEARCH REIMBURSEMENT OF UP TO $302.5 MILLION.FULCRUM THERAPEUTICS INC - FULCRUM MAY ALSO BE ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS IN MID-SINGLE-DIGIT TO LOW DOUBLE-DIGIT RANGE.FULCRUM THERAPEUTICS - IF MYOKARDIA CHOOSES COMMERCIALIZE PRODUCTS DIRECTED TO ADDITIONAL TARGETS, CO MAY BE ELIGIBLE FOR UP TO $150.0 MILLION IN PAYMENTS.

Myokardia Inc - Plans To Start Phase 2 Genetic Dcm Study In Second Half Of 2020

MyoKardia Inc <MYOK.O>::MYOKARDIA ANNOUNCES POSITIVE DATA FROM PHASE 2A CLINICAL TRIAL OF DANICAMTIV PRESENTED AT ESC’S HFA DISCOVERIES WITH SIMULTANEOUS PUBLICATION IN EUROPEAN JOURNAL OF HEART FAILURE.MYOKARDIA - NEW OBSERVATIONS SHOW IMPROVEMENTS IN LEFT ATRIAL VOLUME AND FUNCTION, KEY PROGNOSTIC INDICATORS OF ATRIAL FIBRILLATION.MYOKARDIA INC - IN PHASE 2A STUDY, DANICAMTIV WAS GENERALLY WELL-TOLERATED.MYOKARDIA - NONCLINICAL STUDIES INDICATED DANICAMTIV DIRECTLY ACTIVATES LEFT VENTRICLE & LEFT ATRIUM.MYOKARDIA INC - INTENDS TO ADVANCE DANICAMTIV INTO TWO PHASE 2 CLINICAL TRIALS IN DISTINCT PATIENT SUBGROUPS.MYOKARDIA INC - PLANS TO START PHASE 2 GENETIC DCM STUDY IN SECOND HALF OF 2020.MYOKARDIA - EXPECTS TO INITIATE PHASE 2 STUDY IN PATIENTS WITH SYSTOLIC HEART FAILURE & PAROXYSMAL OR PERSISTENT ATRIAL FIBRILLATION IN H1 2021.MYOKARDIA INC - ONE SERIOUS ADVERSE EVENT REPORTED DURING STUDY WAS AN INCIDENCE OF HYPERKALEMIA WHICH RESOLVED.MYOKARDIA - DANICAMTIV SHOWED IMPROVEMENTS IN CARDIAC CONTRACTILITY, PRESERVED DIASTOLIC FUNCTION IN THOSE WITH STABLE HEART FAILURE WITH LOWER EJECTION FRACTION.

Myokardia Announces Pricing Of Public Offering Of Common Stock

May 13 (Reuters) - MyoKardia Inc <MYOK.O>::MYOKARDIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.MYOKARDIA INC - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5,250,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $105.00 PER SHARE.

MyoKardia Announces Proposed Public Offering Of Common Stock

May 11 (Reuters) - MyoKardia Inc <MYOK.O>::MYOKARDIA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.MYOKARDIA INC - COMMENCED A PROPOSED UNDERWRITTEN PUBLIC OFFERING TO SELL $450.0 MILLION IN SHARES OF ITS COMMON STOCK.MYOKARDIA - EXPECTS TO GRANT UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO $67.5 MILLION IN ADDITIONAL SHARES OF COMMON STOCK AT PUBLIC OFFERING PRICE.

MyoKardia Announces Primary, All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten

May 11 (Reuters) - MyoKardia Inc <MYOK.O>::MYOKARDIA ANNOUNCES PRIMARY AND ALL SECONDARY ENDPOINTS MET IN PHASE 3 EXPLORER CLINICAL TRIAL OF MAVACAMTEN FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY.MYOKARDIA ANNOUNCES PRIMARY AND ALL SECONDARY ENDPOINTS MET IN PHASE 3 EXPLORER CLINICAL TRIAL OF MAVACAMTEN FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY.MYOKARDIA INC - MAVACAMTEN WELL TOLERATED; SAFETY RESULTS COMPARABLE TO PLACEBO.MYOKARDIA INC - U.S. REGULATORY SUBMISSION PLANNED FOR EARLY 2021.MYOKARDIA INC - HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENTS IN NYHA CLASSIFICATION.MYOKARDIA INC - 30-WEEK TREATMENT WITH MAVACAMTEN RESULTED IN A HIGHLY STATISTICALLY SIGNIFICANT OUTCOME RELATIVE TO PLACEBO.MYOKARDIA INC - RESULTS FROM PHASE 3 EXPLORER-HCM CLINICAL TRIAL WILL BE SUBMITTED TO A FUTURE PROFESSIONAL MEETING IN 2020.

MyoKardia Announces Positive Topline Data From Its Phase 2 MAVERICK-HCM Clinical Trial Of Mavacamten

Nov 11 (Reuters) - MyoKardia Inc <MYOK.O>::MYOKARDIA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 2 MAVERICK-HCM CLINICAL TRIAL OF MAVACAMTEN.MYOKARDIA INC - ACHIEVED PRIMARY STUDY OBJECTIVE OF SAFETY AND TOLERABILITY IN PATIENTS WITH NON-OBSTRUCTIVE HCM.MYOKARDIA INC - SIGNIFICANT REDUCTIONS IN BIOMARKERS OF CARDIAC STRESS OBSERVED IN PATIENTS ON TREATMENT VERSUS. PLACEBO.MYOKARDIA INC - DATA SUPPORT ADVANCEMENT OF MAVACAMTEN IN NON-OBSTRUCTIVE HCM; REGULATORY UPDATE ANTICIPATED IN FIRST HALF OF 2020.MYOKARDIA INC - PHASE 2 STUDY OF MAVACAMTEN TARGETING SUBGROUP OF PATIENTS WITH DIASTOLIC HEART FAILURE (HFPEF) ANTICIPATED TO BEGIN IN Q2 OF 2020.MYOKARDIA INC - PHASE 2 STUDY OF MAVACAMTEN TARGETING SUBGROUP OF PATIENTS WITH DIASTOLIC HEART FAILURE ANTICIPATED TO BEGIN IN Q2 OF 2020.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up